CIPROFLOXACIN (CIPROFLOXACIN)
CGMP Deviations: N-nitroso-ciprofloxacin results above the FDA recommended interim control limit.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
Severity not yet assessed
We have not scored this recall against our rubric yet, so we are not showing a severity rating or our usual guidance. The agency’s own notice below is the authoritative source — read it first.
Plain-English summary
CGMP Deviations: N-nitroso-ciprofloxacin results above the FDA recommended interim control limit.
The recalled product
- Product
- CIPROFLOXACIN (CIPROFLOXACIN)
- Brand
- CIPROFLOXACIN
- Manufacturer
- Hikma Pharmaceuticals USA INC.
- Category
- Drug — Drugs
- Affected units
- 29,085
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (4)
- Lot# CB496A
- Exp. 12/31/2026 Lot# CB497A
- Exp. 12/31/2026 Lot# CB498A
- Exp. 12/31/2026
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · CIPROFLOXACIN
- ModerateCiprofloxacin Ophthalmic Solution Recalled Nationwide for Defective Container Cap
FDA (Drugs) · 2025-03-26
- HighCiprofloxacin Ophthalmic Eye Drops Recalled Due to Defective Container
FDA (Drugs) · 2025-01-15
- ModerateCiprofloxacin Ophthalmic Solution Recalled Due to Defective Container
FDA (Drugs) · 2024-08-07
- ModerateCiprofloxacin Tablets Recalled for Foreign Material Presence
FDA (Drugs) · 2013-04-03
- LowPack Pharmaceuticals Recalls Ciprofloxacin Tablets Due to Missing Labels
FDA (Drugs) · 2012-07-25
Same manufacturer · Hikma Pharmaceuticals USA INC.
See all →- ModerateHikma Recalls Abirtega Tablets for Weight Uniformity Failures
FDA (Drugs) · 2026-10-28
- ModerateHikma Recalls Ramipril Capsules Due to Process Impurity
FDA (Drugs) · 2026-09-02
- ModerateAlendronate Sodium Oral Solution Recalled for Out-of-Specification Assay Results
FDA (Drugs) · 2026-05-06
- ModerateLorazepam injection vials failed the total related compounds impurity specification
FDA (Drugs) · 2025-08-06
- SevereFDA Recalls Acetaminophen Injection Due to Labeling Mix-up
FDA (Drugs) · 2024-08-28